Lipocine Inc. (LPCN) vs Marker Therapeutics, Inc. (MRKR)
A side-by-side comparison of Lipocine Inc. and Marker Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LPCN
Lipocine Inc.
$2.09HealthcareDelayed quote: Oct 6, 2026, 11:47 AM EDT
MRKR
Marker Therapeutics, Inc.
$1.03HealthcareDelayed quote: Oct 6, 2026, 11:48 AM EDT
Total return — LPCN vs MRKR
growth of $100 · dividends reinvested · last 10yLPCN -97.2% (-30.0%/yr)MRKR -98.2% (-33.2%/yr)LPCN compounded faster over this window
LPCN MRKR
LPCN vs MRKR: by the numbers
- •LPCN is the larger company ($17M vs $17M market cap).
- •Both run net losses; MRKR's is the smaller (-706.23% vs -755.13% net margin).
Metrics side by side
Valuation
| Metric | LPCN | MRKR |
|---|---|---|
| P/S ratio | 10.95 | 13.92 |
| P/B ratio | 0.79 | 1.41 |
Profitability
| Metric | LPCN | MRKR |
|---|---|---|
| Gross margin | -334.26% | 0.00% |
| Operating margin | -524.69% | 0.00% |
| Net margin | -755.13% | -706.23% |
| ROE | -54.45% | -71.57% |
| ROIC | -57.74% | -88.07% |
Growth (annualized)
| Metric | LPCN | MRKR |
|---|---|---|
| Total return CAGR (5Y) | -34.76% | -42.13% |
Frequently asked
- How have LPCN and MRKR total returns compared?
- Over the past 10 years, LPCN delivered -29.99% and MRKR delivered -33.25% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.